{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-038297","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.772720+00:00","generated_at":"2026-06-09T10:49:21.116937+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BriaPro subsidiary files financials; spinout of cancer assets completed Aug 31, 2023","bullets":["BriaPro filed Jul 31, 2023 financials: $1 cash, zero revenue, inactive during period.","On Aug 31, 2023, BriaPro closed spinout of Bria-TILsRx and PKCδ inhibitors from parent BriaCell.","Spinout consideration: 47,945,178 BriaPro shares issued; BriaCell owns ~31,963,452 (2/3).","BriaCell options/warrants adjusted; 2,131,400 options and 8,121,650 warrants outstanding with split exercise prices.","BriaPro notes going concern uncertainty; will need additional financing to develop assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-038297","json":"https://secwatch.observer/filing/0001493152-23-038297.json","markdown":"https://secwatch.observer/filing/0001493152-23-038297.md","text":"https://secwatch.observer/filing/0001493152-23-038297.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223038297/0001493152-23-038297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223038297/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T10:49:21.116937+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}